Scientists at The Wistar Institute found a novel mechanism where astrocytes, the most abundant supporting cells in the brain, also promote cancer cell growth and metastasis in the brain.
Adding Kisqali (ribociclib) to standard hormone therapy significantly extended overall survival for postmenopausal patients with HR+/HER- advanced breast cancer in the phase III MONALEESA-3 trial.
The phase III CheckMate -067 trial continued to demonstrate improved overall survival with the first-line combination of Opdivo (nivolumab) plus Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced metastatic melanoma.
Jevtana (cabazitaxel) demonstrated improved survival over second androgen receptor-targeted agent in patients with metastatic castration-resistant prostate cancer. The data were published Sept. 30 in The New England Journal of Medicine.
Estimated rate of freedom from recurrence of breast cancer at a distant site was 93% at five years, an outcome much better than expected with endocrine therapy alone, data from the TAILORx trial show.
Verzenio (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer previously treated with endocrine therapy.
The efficacy of Alecensa (alectinib) in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, who were identified using liquid biopsy in the phase II/III BFAST study, is consistent with efficacy in those identified by tissue analysis in the phase III ALEX study.
Tecentriq plus chemotherapy showed a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy alone for the first-line initial treatment of patients with previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy.
Results from the phase III BEACON CRC trial show significant improvements in overall survival and objective response rates for the BRAFTOVI Triplet and BRAFTOVI Doublet combination (BRAFTOVI and cetuximab), compared to cetuximab plus irinotecan-containing regimens (Control), and provide analysis of the efficacy and safety of the BRAFTOVI Triplet compared to the BRAFTOVI Doublet.
Combination therapy with mavorixafor and axitinib (Inlyta) demonstrated clinical improvement with encouraging median progression free survival in a heavily pretreated advanced clear cell renal cell carcinoma patient population.
